Acute myeloid leukemia (AML) is a malignant disease characterized by deregulated proliferation of immature myeloid cells. Constitutive activation of the phosphatidylinositol 3-kinase (PI3K)/AKT signaling pathway is frequently detected in approximately 50-70% of AML patients. The gene INPP5D encodes the SH2-containing inositol 5-phosphatase 1 (SHIP1), which is a negative regulator of PI3K/AKT signaling. After lentiviral-mediated gene transfer of INPP5D into CD34 + cells derived from AML patients (n ¼ 12) the granulocyte macrophage-colony stimulating factor (GM-CSF)-dependent proliferation was reduced in all samples analyzed (average 86%; range 72-93%). An enzymatically inactive form of SHIP1 (D672A) had no effect. In addition, SHIP1 reduced the autonomous proliferation of CD34 + cells from a patient with a secondary AML who had a very high peripheral blast count (300 Â 10 9 l À1 ). These data show that SHIP1 can effectively block GM-CSF-dependent and autonomous proliferation of AML cells.
Introduction
The INPP5D gene encodes the SH2-containing inositol 5-phosphatase 1 (SHIP1), which is an important negative regulator of cytokine signaling. 1 Missense mutations in the INPP5D gene have been detected in several patients with acute myeloid leukemia (AML) implicating mutated SHIP1 in the pathogenesis of AML. 2, 3 One of the mutations detected in a patient with AML caused a reduction in SHIP1 activity suggesting a possible tumor suppressor function of SHIP1. 4 Restoration of SHIP1 activity in a human SHIP1 deficient leukemia cell line (Jurkat) resulted in a reduced proliferation owing to an increased transit time through the G 1 phase of the cell cycle. 5 Gene transfer of INPP5D in CD34 + cells from patients with juvenile myeloid leukemia carrying mutations in KRAS2 or PTPN11 reduced their hypersensitivity for granulocyte macrophage-colony stimulating factor (GM-CSF). 6 In this report, we characterized the inhibitory effects of SHIP1 on the GM-CSF-dependent and autonomous proliferation of CD34 + cells from AML patients.
Results and discussion
In this study, the effect of SHIP1 on the proliferation of CD34 + cells purified from the peripheral blood of 12 patients with AML was determined. First, we determined the levels of endogenous SHIP1 protein, which were highly variable in the AML samples analyzed (Figure 1 ). Interestingly, two AML samples, that is, AML5 and AML8, showed a very low expression of SHIP1 suggesting a downregulation of SHIP1 in the leukemia cells from these patients. A downregulation of SHIP1 has been detected in primary samples of patients with Philadelphia chromosome-positive chronic myeloid leukemia and can be experimentally induced in cells by overexpression of BCR/ABL. 7 In AML, such a downregulation of SHIP1 may be mediated by other tyrosine kinases like c-Kit or Flt3. Interestingly, the patient AML8 with very low expression of SHIP1 showed mutations in both, c-Kit (M536I) and Flt3 (internal tandem duplication, amino acids 591-607; data not shown).
Because SHIP1 is a negative regulator of the phosphatidylinositol 3-kinase (PI3K)/AKT signaling pathway, we expected an increased activation of PI3K/AKT signaling in AML samples with low expression of SHIP1. In 8 of the 12 AMLs (67%) analyzed, we observed a constitutive phosphorylation of AKT at serine 473, however, there was no inverse correlation between the levels of phosphoserine AKT (pAKT) and SHIP1 ( Figure 1 ). These data indicate that even a very low expression of SHIP1 as observed in AML8 does not automatically result in a constitutive activation of AKT ( Figure 1) .
Next, the effect of overexpression of SHIP1 on the in vitro proliferation of AML cells was determined. The GM-CSF-dependent proliferation of the transduced cells was reduced by 72-93% in all AML samples analyzed (Figure 2a) . On an average, SHIP1 caused an 86 ± 8% reduction of the proliferation of the CD34 + cells from 12 AML patients (Figure 2b ). An enzymatic inactive form of SHIP1 (D672A) had no effect on the proliferation of AML cells, indicating that the inhibitory effect of SHIP1 is dependent on its enzymatic activity ( Figure 2b ). We further analyzed the effect of SHIP1 on the autonomous proliferation of the CD34 + cells from one AML patient (AML12), who had developed a secondary AML after a myeloproliferative syndrome and showed a very high peripheral blast count (300 Â 10 9 l
À1
). SHIP1 was able to reduce the autonomous proliferation of the CD34 + cells from this patient by 45 ± 2% in comparison to cells expressing enhanced green fluorescent protein (EGFP; EGFP + ), only, or in comparison to nontransduced cells (EGFP À ; Figure 2c ). As observed before, an enzymatic inactive mutant of SHIP1 (D672A) had no effect, underlining the functional role of the enzymatic activity of SHIP1 to mediate its inhibitory function ( Figure 2c) . SHIP1, being an inositol 5-phosphatase, blocks the recruitment and activation of several pleckstrin homology containing proteins (VAV1, 2 and 3, PLC, etc.), in particular Akt, whose activation is strongly dependent on PI3K. 8 The molecular mechanism by which SHIP1 inhibits the proliferation of AML cells is most likely mediated by reducing the levels of PtdIns(3,4,5)P 3 and activated AKT, as observed after SHIP1 expression in Jurkat cells. 5 To address the effect of Akt on the proliferation of AML cells directly, CD34
+ cells from a patient with AML (AML13) were incubated with the Akt inhibitor triciribine and the autonomous proliferation Effects of SHIP1 on acute myeloid leukemia cells A Metzner et al was analyzed by BrdU incorporation. The Akt inhibitor caused a 92% (Po0.01) and 95% (Po0.001) reduction of BrdU incorporation after treatment with 1 and 10 mM triciribine, respectively (Figure 3 ). These data indicate that both, expression of SHIP1 and inhibition of Akt can partially inhibit the autonomous proliferation of AML cells in vitro. As Akt is constitutively activated in several tumors including AML, phospholipids analogs such as perifosine have been used but with the specific aim to activate chemotherapy-dependent apoptosis in cancer cells. 9 Whether overexpression of SHIP1 can sensitize AML cells for treatment with chemotherapeutic substances has to be shown in further experiments.
An interesting question is why the endogenous levels of SHIP1, especially in those AML samples with high amounts of SHIP1, are not sufficient to control the constitutive activation of the PI3K/AKT pathway in the AML cells efficiently. One possibility is that the enzymatic activity of SHIP1 is reduced because of mutations in its catalytic domain, as described for the SHIP mutant V684E detected in a patient with AML. 4 Alternatively, mutations in its interacting domains, such as the SH2 domain (F28L) or the proline rich motifs at the C terminus (P1039S, P1042L), which have been detected in some AML patients, may interfere with the recruitment of SHIP to the cytoplasmic membrane were its substrate PtdIns(3,4,5)P 3 is located. 2 Beside SHIP, another phosphatase regulating the PI3K/AKT pathway is phosphatase and tensin homolog (PTEN), which is dysregulated in several malignant cancer including AML. 10 Downregulation of PTEN, but not SHIP1, has been described in some cases of AML. 11 We have detected very low levels of SHIP1 in 2 out of 12 AML patients, suggesting that SHIP1 is downregulated in some cases of AML. The exact frequency of downregulation of SHIP1 in AML has to be analyzed in a larger study.
In summary, our data demonstrate that overexpression of SHIP1 can reduce the GM-CSF-dependent and autonomous proliferation of CD34 + cells from patients with AML. This effect of SHIP1 is dependent on the enzymatic activity of SHIP1. The inhibitory effect of SHIP1 on the proliferation of AML cells suggests a potential role of SHIP1 for gene therapy of patients with AML. Overexpression of SHIP1 in AML cells may reduce leukemia cell load thereby improving survival and response in combination with standard chemotherapy or alternative therapy (that is, monoclonal antibodies or tyrosine kinase inhibitors). The severe side effects and limitations of conventional chemotherapy and hematopoietic stem cell transplantation indicate the urgent need for any new treatment strategy for AML patients.
Materials and methods

Patient samples
Peripheral blood samples were obtained from 13 patients with AML after informed consent within a protocol approved by the medical board of Hamburg (OB/7/01). The AML patients were classified according to the French-American-British classification as M1 (n ¼ 2, AML10, 13), M2 (n ¼ 3, AML4-6), M3 (n ¼ 1, AML8), M4 (n ¼ 4, AML2, 3, 7, 9), M5 (n ¼ 1, AML1), secondary AML after MDS (n ¼ 1, AML11) and secondary AML after MPS (n ¼ 1, AML12).
Lentiviral vectors
Human SHIP1 cDNA and an enzymatic inactive SHIP1 mutant (D672A) 5, 6 were cloned in the lentiviral vector pRRL.PPT.CMV.GFPpre. 293T cells were cultured in Dulbecco's modified Eagle's medium supplemented with 10% fetal calf serum and 2 mM glutamine. Pseudotyped lentiviral viruses were generated by transient lipofectamine-mediated cotransfection of the plasmids pRRL.PPT.CMV.GFPpre (5 mg), pHCMV-VSV-G (2 mg), pMDLg/p (12 mg) and of pRSV-Rev (5 mg). Virus containing supernatants were collected, filtered and stored at À80 1C until used. The titer was determined on human HT1080 cells and ranged from 5 Â 10 5 to 1 Â 10 6 infectious particles per ml.
Transduction, cell sorting and proliferation assays of CD34 + cells
Enriched CD34 + cells were cultured in serum-free StemSpan medium (StemCell Technologies, St Katharinen, Germany) supplemented with Flt3 ligand (100 ng ml À1 ), stem cell factor (100 ng ml À1 ), thrombopoietin (20 ng ml
À1
) and interleukin-6 (20 ng ml
; PeproTech, St Katharinen, Germany). After 48 h, 5 Â 10 5 of the prestimulated CD34 + cells were transferred in 1 ml serum-free medium and 1 ml of viral supernatant was added. The transduction was repeated twice. Transduced cells expressing the EGFP were sorted with a fluorescence-activated cell sorter (FACS)Aria (Becton Dickinson, Heidelberg, Germany) and cultured at 1 Â 10 4 cells per ml in serum-free expansion medium (StemCell Technologies) supplemented with human recombinant GM-CSF (10 ng ml À1 ). The number of cells was counted 10 days after plating. The Akt inhibitor V (triciribine) was purchased from Merck/Calbiochem (Nottingham, UK) and used at a final concentration of 1 and 10 mM. Effects of SHIP1 on acute myeloid leukemia cells A Metzner et al
